DGAP-Ad hoc: QIAGEN N.V. <QIA> deutsch - 500 Beiträge pro Seite

[ad_hoc [wO]]

DGAP-Ad hoc: QIAGEN N.V. <QIA> deutsch

QIAGEN veröffentlicht seine Geschäftszahlen für das erste Quartal 2002

Ad-hoc-Mitteilung übermittelt durch die DGAP. Für den Inhalt der Mitteilung ist der Emittent verantwortlich.

--------------------------------------------------------------------------------

QIAGEN veröffentlicht seine Geschäftszahlen für das erste Quartal 2002 Venlo, Niederlande, 06. Mai, 2002 : Der Vorstand der QIAGEN N.V. (Nasdaq: QGENF, Neuer Markt: QIA) meldet heute die Ergebnisse für das erste Quartal 2002. Im ersten Quartal stieg der konsolidierte Umsatz von QIAGEN im Vergleich zum Vorjahr um 12% von US $63,1 auf US $70,5 Millionen. Zusätzlich wurden im Wert von US $2,0 Million Geräte zur Herstellung von synthetischen Nukleinsäuren an Xeragon geliefert, die Anfang Februar bestellt wurden. Da QIAGEN die Xeragon, Inc. am 17. April 2002 akquirierte, sind diese Lieferungen rückwirkend als Lieferungen an eine Tochtergesellschaft bilanziert worden und daher nicht im konsolidierten Umsatz reflektiert. Unter Einbeziehung dieser Lieferungen an die Xeragon Inc. und unter Verwendung gleicher Umrechnungskurse wie im gleichen Quartal des Vorjahres stieg der Umsatz um 18% auf US $74,6 Millionen. Bereinigt um die Auswirkungen der Akquisition von Xeragon und akquisitionsbedingter Aufwendungen im ersten Quartal 2001 stieg das operative Ergebnis um 20% von US $14,5 Millionen auf US $17,4 Millionen, der konsolidierte Gewinn nach Steuern um 31% von US $8,0 Millionen auf US $10,5 Millionen und der (diluted) Gewinn pro Aktie von US $0,06 auf US $0,07. Ohne Bereinigung um die Effekte aus den Akquisitionen in beiden Quartalen stieg der operative Gewinn um 36% auf US $15,7 Millionen, der konsolidierte Gewinn nach Steuern um 60% auf US $9,5 Millionen und der Gewinn pro Aktie um 75% von US $0,04 im ersten Quartal 2001 auf US $0,07 im ersten Quartal 2002. QIAGEN berichtet, dass die Produkte des Unternehmens in vielen neuen und interessanten Anwendungen eingesetzt werden. So meldet QIAGEN auch eine Entwicklungs- und Co-Marketingvereinbarung im Bereich Laser Mikrosektion mit Leica Microsystems AG und eine Liefervereinbarung über SensiChip Systeme mit der Axxima Pharmaceuticals AG. Axxima und QIAGEN entwickeln zusätzlich gemeinsam aus Gendaten synthetische Nukleinsäuren zur Detektion von Kinasen und Phosphatasen für die Anwendung auf SensiChip Systemen. Die SensiChip Systeme wurden in QIAGEN´s Allianz mit der Zeptosens AG entwickelt und sind nach einem Jahr Vertrieb über Technologie-Access-Programme vor wenigen Tagen den breiten Märkten zugänglich gemacht worden. Kontakt: IR QIAGEN N.V.; Tel.: [phone]; Email: [e-mail]

Ende der Ad-hoc-Mitteilung (c)DGAP 06.05.2002

--------------------------------------------------------------------------------

WKN: 901626; ISIN: NL0000240000; Index: NEMAX50 Notiert: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, München, Hannover und Stuttgart

Autor: import DGAP.DE (),22:14 06.05.2002

[thetoto]

QIAGEN Reports First Quarter 2002 Results; 23% Revenue Growth in Core Consumables Business and EPS of $ 0.07

VENLO, Netherlands, May 6 /PRNewswire-FirstCall/ -- QIAGEN N.V. (Nasdaq: QGENF; Neuer Markt: QIA) today announced the results of operations for its first quarter 2002.

The Company reported that consolidated net sales for its first quarter increased 12% to $70.5 million, from $63.1 million for the same period in 2001. In addition, QIAGEN shipped approximately $2.0 million in liquid handling instruments for nucleic acid synthesis to Xeragon Inc, which had placed these purchases in early February. Including these shipments to Xeragon Inc. and using identical foreign exchange rates for both periods, net sales would have been $74.6 million, a growth rate of 18%. As a result of QIAGEN`s acquisition of Xeragon on April 17, QIAGEN decided to account the shipments to Xeragon as sales to a subsidiary and has therefore excluded them from net sales and income for the first quarter ended March 31, 2002. Excluding these effects of the acquisition of Xeragon in 2002 and acquisition related expenses in the prior year period, operating income for the first quarter 2002 increased 20% to $17.4 million from $14.5 million in the comparable period in 2001, net income increased 31% to $10.5 million from $8.0 million and diluted earnings per share increased 17% to $0.07 (based on 145.2 million average shares and share equivalents outstanding) from $0.06 (based on 145.0 million average shares and share equivalents outstanding) in the comparable quarter of 2001. Including the effects of acquisitions in both periods, operating income increased 37% to $15.7 million from $11.5 million, net income increased 60% to $9.5 million from $6.0 million and diluted earnings per share increased 75% to $0.07 from $0.04 in the comparable quarter of 2001.

"We are pleased with our sales performance during the challenging first quarter of 2002," said Dr. Metin Colpan, QIAGEN`s Chief Executive Officer. "We are reporting net sales of $70.5 million, a 12% increase over the prior year. In addition, we had $2.0 million in instrument shipments to Xeragon, Inc., which are not included in our net sales results as they are being treated as sales to a subsidiary as we later acquired the company. Moreover, we are encouraged to be seeing a gradual improvement in market conditions," said Dr. Metin Colpan, QIAGEN`s Chief Executive Officer. "The delay in the approval processes for the academic research budgets in the United States weighed heavily on QIAGEN`s academic customers. This customer group accounts for approximately 50% of QIAGEN`s net sales. As the budgets of the National Institutes of Health were approved in late January, this situation has started to improve. The overall research spending by large pharmaceutical companies, who represent approximately 35% of QIAGEN`s revenue base, slowed significantly during the first quarter which disproportionately affected sales in the United States. We believe that this market, too, is beginning to show signs of improving. QIAGEN`s products are addressing exciting opportunities of which some are outlined in recent announcements regarding Xeragon, Axxima and Leica."

"Adjusted for currency fluctuations, net sales of QIAGEN`s core nucleic acid separation and purification and related consumables increased 23% in the first quarter of 2002 compared to the prior year period and represented 77% of net sales," said Peer M. Schatz, Chief Financial Officer. Net sales in Europe and Asia grew significantly faster than net sales in the United States which represent approximately 55% of consolidated net sales. These trends had been expected and are built into the Company`s financial guidance."

QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the United States, Japan, the United Kingdom, Switzerland, France, Italy, Australia and Canada, believes it is the world`s leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids. The Company has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products and related services. QIAGEN`s products are sold in more than 42 countries throughout the world to academic research markets and to leading pharmaceutical and biotechnology companies. In addition, the Company is positioning its products for sale into developing commercial markets, including DNA sequencing and genomics, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. QIAGEN employs over 1,600 people worldwide. Further information on QIAGEN can be found at http://www.qiagen.com.

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN`s products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, nucleic acid-based molecular diagnostics market, genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN`s products (including seasonal fluctuations), difficulties in successfully adapting QIAGEN`s products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC).


QIAGEN N.V.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME

Three months
ended March 31,
2002 2001
Net sales $70,530,000 $63,147,000
Cost of sales 21,045,000 17,291,000
Gross profit 49,485,000 45,856,000

Operating Expenses:
Research and development 6,436,000 6,662,000
Sales and marketing 17,859,000 14,572,000
General and administrative 9,478,000 10,107,000
Acquisition costs -- 3,000,000
Total operating expenses 33,773,000 34,341,000

Income from operations 15,712,000 11,515,000

Other Income (Expense):
Interest income 338,000 702,000
Interest expense (651,000) (520,000)
Research and development grants 136,000 186,000
Loss on foreign currency
transactions (140,000) (117,000)
Loss from equity method investee (381,000) (412,000)
Other miscellaneous expense, net (10,000) (74,000)
Total other expense (708,000) (235,000)

Income before provision for income
taxes
and minority interest 15,004,000 11,280,000
Provision for income taxes 5,498,000 5,315,000
Minority interest -- 8,000
Net income $9,506,000 $5,957,000


Weighted average number of diluted
common shares 145,173,000 145,038,000

Diluted net income per common share $0.07 $0.04
Diluted net income per common share
excluding acquisition related
items $0.07 $0.06


QIAGEN N.V.
CONDENSED CONSOLIDATED BALANCE SHEETS

March 31, December 31,
2002 2001
Assets

Current Assets:
Cash and cash equivalents $42,949,000 $56,460,000
Marketable securities 21,328,000 22,512,000
Notes receivable 3,920,000 3,844,000
Accounts receivable, net 46,040,000 39,955,000
Income taxes receivable 2,183,000 2,439,000
Inventories 35,535,000 31,883,000
Deferred income taxes 10,518,000 11,123,000
Prepaid expenses and other 8,967,000 9,115,000
Total current assets 171,440,000 177,331,000

Property, plant and equipment, net 175,194,000 160,365,000
Long-term marketable securities 2,173,000 2,759,000
Intangible assets, net 7,269,000 7,140,000
Deferred income taxes 1,804,000 1,804,000
Other assets 7,914,000 7,569,000
Total assets $365,794,000 $356,968,000

Liabilities and Shareholders` Equity

Current Liabilities:
Lines of credit $4,498,000 $6,038,000
Short-term debt -- 281,000
Current portion of long-term debt 1,114,000 1,138,000
Current portion of capital lease
obligations 1,086,000 1,085,000
Accounts payable 22,075,000 20,262,000
Accrued liabilities 21,351,000 20,235,000
Income taxes payable 6,179,000 8,434,000
Deferred income taxes 4,417,000 410,000
Total current liabilities 60,720,000 57,883,000

Long-Term Liabilities:
Long-term debt, net of current
portion 68,852,000 70,720,000
Capital lease obligations, net of
current portion 9,986,000 10,463,000
Other 4,950,000 4,927,000
Total long-term liabilities 83,788,000 86,110,000

Commitments and Contingencies

Shareholders` Equity:
Common shares, EUR .01 par value:
Authorized -- 260,000,000 shares
Issued and outstanding--
143,678,771 shares
in 2002 and 143,463,800
shares in 2001 1,460,000 1,458,000
Additional paid-in-capital 124,295,000 123,117,000
Retained earnings 106,784,000 97,278,000
Accumulated other comprehensive
loss (11,253,000) (8,878,000)
Total shareholders` equity 221,286,000 212,975,000

Total liabilities and
shareholders` equity $365,794,000 $356,968,000



/CONTACT: Peer M. Schatz, Chief Financial Officer, [phone], [e-mail], or Dr. Solveigh Maehler, Investor Relations, [phone], [e-mail], both of QIAGEN N.V.; or Veronica Sellar, [phone], or Mary Claire Duch, [phone], both of Noonan Russo Communications/